A Q2 Deep Dive: Product Momentum, China Recovery, and Operating Leverage Drive Results

Life sciences tools company Agilent Technologies (NYSE:A) announced better-than-expected revenue in Q2 CY2026, with sales up 8.1% year on year to $1.88 billion. Guidance for next quarter’s revenue was better than expected at $1.99 billion at the midpoint, 1% above analysts’ estimates. Its non-GAAP profit of $1.62 per share was 9% above analysts’ consensus estimates.

Is now the time to buy A? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Agilent’s second quarter results were well received, as the company delivered revenue and adjusted earnings above Wall Street’s expectations. Management credited the quarter’s outperformance to broad-based demand across its core end markets, with notable strength in pharma, advanced materials, and diagnostics. CEO Padraig McDonnell pointed to the company’s Ignite Operating System and strategic pricing initiatives as key levers that improved operational discipline and margin expansion. Robust growth in China and continued instrument replacement cycles also supported the results.

Looking to the remainder of the year, Agilent’s updated outlook reflects confidence in ongoing end market improvement and recent product launches. Management highlighted momentum in China, increased investment in biotech and pharma, and early gains from reshoring trends as drivers for sustained growth. CFO Adam Elinoff noted that efficiencies from the Ignite program and continued pricing power are expected to support margin expansion, stating, “Our operating profit is growing faster than sales, giving us financial flexibility.”

Key Insights from Management’s Remarks

Management attributed the strong quarter to improved commercial execution, new product traction, and operational efficiencies, while also highlighting emerging multi-year growth drivers.

• Pharma and biotech demand: Agilent’s pharma division achieved 12% growth, with biotech growing double digits and small molecule growing mid-single digits. The specialty CDMO (Contract Development and Manufacturing Organization) business grew nearly 30%, supported by GLP-1 therapeutic demand and capacity expansion.
• Advanced materials and semiconductor momentum: The chemicals and advanced materials segment (CAM) grew 7%, ahead of expectations, with advanced materials delivering double-digit growth tied to investments in semiconductor manufacturing and AI infrastructure build-outs. Management noted that instrument demand typically follows major semiconductor fab investments by 18-24 months, creating a long runway for growth.
• China market acceleration: China delivered 9% revenue growth, surpassing expectations due to strong performance in pharma and food end markets, competitive wins, and new partnerships for AI-driven drug discovery workflows. Management emphasized that this momentum occurred without significant benefit from local stimulus.
• Product launch success: Recent launches, including the 9500 Triple Quad ICP-MS, new flagship GC systems, and Altura columns, saw stronger-than-anticipated adoption across regions. The 9500 system, designed for increased productivity in analytical labs, exceeded ramp-to-volume targets within its first months of shipment.
• Operational efficiency via Ignite: The Ignite Operating System drove improvements in strategic pricing, procurement, supply chain agility, and digital transformation. These initiatives contributed to a 210 basis point year-over-year expansion in non-GAAP operating margin (excluding tariff refunds), while enabling rapid response to shifting demand and material cost pressures.

Drivers of Future Performance

Management expects continued end market recovery, accelerated new product adoption, and operational leverage to shape the company’s outlook.

• Sustained momentum in China and pharma: Management anticipates that ongoing recovery in China, combined with strong investment from multinational and local pharma companies, will underpin near-term growth. Increased biotech funding and a robust drug development pipeline are expected to support demand for both analytical instruments and CDMO services.
• Reshoring and semiconductor opportunity: Agilent is positioned to benefit from North American and global reshoring trends, particularly in pharma and semiconductor manufacturing. Orders from major pharma customers and a growing installed base in semiconductor supply chains are projected to ramp up, with management expecting meaningful revenue contributions in 2027 and beyond.
• Margin expansion through Ignite: The Ignite program is expected to continue delivering operating leverage via pricing discipline, supply chain optimization, and digital initiatives. Management noted that these structural improvements should help offset inflationary pressures and support double-digit non-GAAP earnings growth targets.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will closely watch (1) the pace of adoption for Agilent’s new instrument platforms and Altura columns across global markets, (2) the sustainability of China’s recovery and its impact on order growth, and (3) early revenue contributions from pharma reshoring and semiconductor supply chain investments. Continued operational improvements through Ignite and margin performance will also be key signposts.

Agilent currently trades at $158.09, up from $155.20 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.